C

Chiome Bioscience Inc
TSE:4583

Watchlist Manager
Chiome Bioscience Inc
TSE:4583
Watchlist
Price: 259 JPY 1.57%
Market Cap: 16.6B JPY
Have any thoughts about
Chiome Bioscience Inc?
Write Note

Chiome Bioscience Inc
Income to Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chiome Bioscience Inc
Income to Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income to Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
C
Chiome Bioscience Inc
TSE:4583
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CMIC Holdings Co Ltd
TSE:2309
Income to Minority Interest
-ÂĄ271m
CAGR 3-Years
N/A
CAGR 5-Years
-93%
CAGR 10-Years
N/A
Medinet Co Ltd
TSE:2370
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CellSource Co Ltd
TSE:4880
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Linical Co Ltd
TSE:2183
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WDB coco Co Ltd
TSE:7079
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Chiome Bioscience Inc
Glance View

Market Cap
15.9B JPY
Industry
Life Sciences Tools & Services

Chiome Bioscience, Inc. engages in the development and sale of antibody drugs through the Autonomous Diversifying Library (ADLib) system. The company is headquartered in Shibuya-Ku, Tokyo-To and currently employs 37 full-time employees. The company went IPO on 2011-12-20. The firm operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.

Intrinsic Value
31.11 JPY
Overvaluation 88%
Intrinsic Value
Price
C

See Also

Back to Top